• Home
  • Investors
    • News Archive
    • Share Information
      • Shareholder Service
      • General Meetings
    • Reports
    • Board and Management
  • Contact

You are here

Home » Investors

News

Q2 2009: Strong foundation for growth
Invitation to presentation of second quarter and first half of 2009 financials
Successful completion of clinical trial for NorDiag's new Bullet BUGS'n BEADS(TM) kit
Strategic deal drives top-line growth
A step forward for NorDiag on the tuberculosis project
Write down of excess value of NOK 23.3 million
Successful completion of NorDiag's swab sample clinical trial tailored to the BD Probetec (TM) ET system
Innovation Norway grants NorDiag new loan of NOK 6 million
Surrender of shares and warrants for primary insider
NorDiag Q1 2009: Business develops according to plan
Cooperation agreement with Kitron
Invitation to presentation of the 1st quarter 2009 results
New distributor in USA
Minutes from Annual General Meeting
NOTICE OF GENERAL MEETING
SUCCESSFUL COMPLETION OF CLINICAL TRIAL FOR NORDIAG's "Bullet" Instrument for automated sample preparation of swab samples
Annual overview
New distributor in France
Commencement of the first exercise period for Class A Warrants and Class B Warrants
NorDiag Q4 2008: Runrate of operating revenues more than doubled

Pages

  • « first
  • ‹ previous
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • next ›
  • last »
News archive

NORDA ASA  ♦   C/O  Andenæsgruppen  ♦   Stortingsgaten 28  ♦   0161 Oslo  ♦   Norway  ♦   Phone: +47 924 23 561  ♦   web: www.nordasa.no